Version 1
: Received: 19 April 2024 / Approved: 22 April 2024 / Online: 23 April 2024 (12:49:33 CEST)
How to cite:
Xiong, S.; Yang, C.; Liao, X.; Fu, K.; Zhang, L.; Wang, T.; Long, J.; Li, Y.; Li, Y. Clinical Research and Mechanistic Exploration of Combined Treatment with Everolimus and EP Chemotherapy in Large Cell Neuroendocrine Carcinoma. Preprints2024, 2024041437. https://doi.org/10.20944/preprints202404.1437.v1
Xiong, S.; Yang, C.; Liao, X.; Fu, K.; Zhang, L.; Wang, T.; Long, J.; Li, Y.; Li, Y. Clinical Research and Mechanistic Exploration of Combined Treatment with Everolimus and EP Chemotherapy in Large Cell Neuroendocrine Carcinoma. Preprints 2024, 2024041437. https://doi.org/10.20944/preprints202404.1437.v1
Xiong, S.; Yang, C.; Liao, X.; Fu, K.; Zhang, L.; Wang, T.; Long, J.; Li, Y.; Li, Y. Clinical Research and Mechanistic Exploration of Combined Treatment with Everolimus and EP Chemotherapy in Large Cell Neuroendocrine Carcinoma. Preprints2024, 2024041437. https://doi.org/10.20944/preprints202404.1437.v1
APA Style
Xiong, S., Yang, C., Liao, X., Fu, K., Zhang, L., Wang, T., Long, J., Li, Y., & Li, Y. (2024). Clinical Research and Mechanistic Exploration of Combined Treatment with Everolimus and EP Chemotherapy in Large Cell Neuroendocrine Carcinoma. Preprints. https://doi.org/10.20944/preprints202404.1437.v1
Chicago/Turabian Style
Xiong, S., Yongsheng Li and Yan Li. 2024 "Clinical Research and Mechanistic Exploration of Combined Treatment with Everolimus and EP Chemotherapy in Large Cell Neuroendocrine Carcinoma" Preprints. https://doi.org/10.20944/preprints202404.1437.v1
Abstract
First-line treatment for advanced large-cell neuroendocrine carcinoma of the lung (LCNEC) has limited efficacy. This study aimed to explore the efficacy and safety of everolimus combined with EP regimen chemotherapy (etoposide + cisplatin, EP) in the first-line treatment for LCNEC. The patients were randomly assigned to the experimental or control group, with 20 patients in each group. The experimental group received the mTOR inhibitor everolimus 5 mg once a day combined with EP ivgtt, d1-3, every 3 weeks for 4–6 cycles. The control group received EP only and the infusion method was the same as that of the experimental group. The safety in the experimental group was controllable and not inferior to that in the control group. Serious adverse effects were observed in approximately 10% of patients. Objective response rate (ORR) for the experimental and control groups were 15% vs. 0 (P=0.231), disease control rate (DCR) was 100% vs. 32% (P
Keywords
cisplatin; etoposide; everolimus; LCNEC; lung cancer
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
